Sutro Biopharma - Asset Resilience Ratio
Sutro Biopharma (STRO) has an Asset Resilience Ratio of 48.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Sutro Biopharma's Asset Resilience Ratio has changed over time. Check STRO capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sutro Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Sutro Biopharma worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $101.67 Million | 48.49% |
| Total Liquid Assets | $101.67 Million | 48.49% |
Asset Resilience Insights
- Very High Liquidity: Sutro Biopharma maintains exceptional liquid asset reserves at 48.49% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Sutro Biopharma Industry Peers by Asset Resilience Ratio
Compare Sutro Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Sutro Biopharma (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Sutro Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 32.69% | $126.59 Million | $387.21 Million | -32.39pp |
| 2023-12-31 | 65.08% | $306.35 Million | $470.74 Million | -5.47pp |
| 2022-12-31 | 70.55% | $287.11 Million | $406.94 Million | +21.48pp |
| 2021-12-31 | 49.07% | $167.52 Million | $341.41 Million | +7.97pp |
| 2020-12-31 | 41.10% | $161.99 Million | $394.11 Million | -31.10pp |
| 2019-12-31 | 72.20% | $112.90 Million | $156.37 Million | +36.71pp |
| 2018-12-31 | 35.49% | $79.19 Million | $223.14 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $40.77 Million | -- |
| 2016-12-31 | 51.86% | $35.93 Million | $69.28 Million | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid … Read more